In a phase 3 trial of 242 patients whose cancer had spread to the brain, splitting stereotactic radiosurgery into three to five sessions after a tumor was surgically removed lowered the chance that the cancer returned at the surgical site, compared with a single high-dose session.
The results were presented Sept. 28 at the American Society for Radiation Oncology (ASTRO) annual meeting in Boston. They have not yet been published in a peer-reviewed journal.
